Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Lymphocyte production" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The production of lymphocytes begins in bone marrow as B cells or T cells in a process called hematopoiesis. These cells then grow and develop into the respective lymphocytes.
Treatment of immunological disorders using anti-dc30 antibodies
InactiveUS20050123536A1Enhancing cytotoxicEnhancing cytostatic effectOrganic active ingredientsSenses disorderDiseaseAntibody conjugate
The present invention relates to methods for the treatment of immunological disorders other than cancer, comprising administering proteins characterized by their ability to bind to CD30 and exert a cytostatic or cytotoxic effect on an activated lymphocyte. Such proteins include monoclonal antibodies AC10 and IleFi1. AC10 and HeFi-1 derivatives, and antibodies that compete with AC10 and HeFi-1 for binding to CD30. Other such proteins include multivalent anti-CD30 antibodies and anti-CD30 antibodies conjugated to cytotoxic agents. Treatment modalities with antibodies of the invention are also provided.
Owner:SEATTLE GENETICS INC
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
InactiveUS20030008816A1Improve complianceFunction increaseAntibacterial agentsCosmetic preparationsCell adhesionPulmonary compliance
The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.
Owner:CC10 SWEDEN +4
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
InactiveUS20060025348A1Improve complianceFunction increaseCosmetic preparationsPeptide/protein ingredientsCell adhesionPulmonary compliance
The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.
Owner:CC10 SWEDEN
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
InactiveUS20020169108A1Improve complianceFunction increaseCosmetic preparationsCell receptors/surface-antigens/surface-determinantsCell adhesionVascular endothelium
The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.
Owner:CC10 SWEDEN
Adoptive cell therapy with specific regulatory lymphocytes
InactiveUS20140356318A1BiocidePeptide/protein ingredientsTolerance inductionAdoptive cellular therapy
The present invention comprises a method of treatment of an autoimmune disease involving a specific tolerance induction (“STI”) event, wherein the method includes: collecting a first sample from the patient prior to the STI event; detecting an STI event or performing a procedure that correlates in time to an STI event; collecting a second sample from the patient after the STI event; preparing lymphocytes from the first and second samples; preparing and sequencing DNA or cDNA from the prepared lymphocytes; identifying sequences of prevalent T or B cell receptors (“prevalent receptor sequences”) among the lymphocytes of the second sample; selecting a regulatory lymphocyte that carries at least one prevalent receptor sequence, which selected regulatory lymphocyte (i) expresses at least one prevalent receptor sequence or (ii) is generated from an autologous or allogeneic naïve lymphocyte, which naïve lymphocyte is engineered and induced to become a regulatory lymphocyte that expresses at least one prevalent receptor sequence; culturing the selected regulatory lymphocyte, thereby generating daughter cells of said regulatory lymphocyte; and administering the daughter cells to the patient.
Owner:BARKEN ISRAEL
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
InactiveUS20090029917A1Improve complianceFunction increaseCosmetic preparationsCell receptors/surface-antigens/surface-determinantsCell adhesionVascular endothelium
The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.
Owner:PILON APRILE L +7
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
InactiveUS20040047857A1Improve complianceFunction increaseCosmetic preparationsFibrinogenCell adhesionPulmonary compliance
The present invention provides methods and compositions for the treatment of fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH.
Owner:CC10 SWEDEN
Amphipathic self-assembly ultra-short peptide nano hemostatic material
ActiveCN105085622ARich varietyLow toxicityPeptidesAbsorbent padsHemostatic functionBiocompatibility Testing
The invention aims to provide amphipathic self-assembly ultra-short peptide. The amino acid sequence general formula of the peptide is I3-X-Q-G-K(1-2). According to the amphipathic self-assembly ultra-short peptide, the content of amino acid is small, synthesis cost is low, and synthesis conditions can be controlled easily; high-strength in-situ hydrogel can be formed at the moment the ultra-short peptide makes contact with blood, so that a fast hemostatic function is achieved; meanwhile, the series short peptide is low in toxicity, good in biocompatibility and capable of not causing a non-specific immunity reaction of lymphocyte, thereby being an ideal nano hemostatic material. By the application of the amphipathic self-assembly ultra-short peptide, the variety of existing nano medicine materials can be enriched, and it is of great significance to the life and health of people.
Owner:CHINA UNIV OF PETROLEUM (EAST CHINA)
Water-in-oil-in-water type vaccine adjuvant and application thereof
InactiveCN106511995AImprove immunityReduce oil consumptionSsRNA viruses negative-senseSsRNA viruses positive-senseAdjuvantInjection site
The invention provides a water-in-oil-water type vaccine adjuvant and application thereof. According to the technical scheme, ingredients which conform to large production demands and have immunopotentiation are preferred, according to a controlled release principle of a water-in-oil-water type microsphere, an adding mode is designed, thus the water-in-oil-water type vaccine adjuvant more effectively directly acts on an immune cell, and the immune potency is improved. Compared with an regular adjuvant in the prior art, the prepared water-in-oil-water type vaccine adjuvant has reasonable controlled release, target and an isolation characteristic, and after poultry is injected with a vaccine, the water-in-oil-water type microsphere timely metabolizes and breaks so as to comprehensively motivate a poultry lymphocyte to generate an antibody. An immune reinforcing agent with a heavy water phase can be lastingly and slowly release in a subsequent immune cell infiltration process to make bioavailability of the immune reinforcing agent maximize, it is shown that an injected part is well absorbed, an injected animal fast generates immunoprotection, and not only short-term immunity can be induced, but also long-term immunity can be induced.
Owner:天津三江永利生物科技有限公司
Recombinant porcine parvovirus-like particle and its preparation method and application
ActiveCN107227311AStimulationImprove the ability to produce cytokinesPolypeptide with localisation/targeting motifViral antigen ingredientsAdjuvantTransfer vector
The invention discloses a recombinant porcine parvovirus-like particle. A preparation method of the recombinant porcine parvovirus-like particle comprises connecting a TAT protein transduction domain and an antigen VP2 gene for forming a PPV empty capsid protein, carrying out cloning in a baculovirus transfer vector to obtain a homologous recombinant vector, carrying out packaging to obtain a recombinant baculovirus containing a PPV VP2 protein and a TAT protein transduction domain, infecting an insect cell, and expressing a recombinant TAT-VP2 protein fused with the PPV VP2 protein and the TAT protein transduction domain to obtain the parvovirus-like particle (VLPs). A research result shows that the recombinant porcine parvovirus-like particle and an adjuvant infecting an animal can effectively stimulate the PPV-specific antibody production and improve a lymphocyte production capability of lymphocyte. Therefore, the recombinant porcine parvovirus-like particle can be used to develop a novel high-efficiency PPV subunit vaccine having good immune effects.
Owner:GUANGXI VETERINARY RES INST
HSV-2 antigen based DC cell and targeting immune cell population, and preparation method and application thereof
InactiveCN104830781ASafe and efficient preparationAddress toxicityAntiviralsMammal material medical ingredientsAntigenPeripheral blood mononuclear cell
The invention discloses a DC cell and a targeting immune cell population, and a preparation method and application thereof. The preparation method of DC cells includes the steps of: conducting first induced differentiation culture on mononuclear cells in order to obtain immature DC cells; transfecting the immature DC cells by using HSV-2 antigen mRNA, so as to obtain transfected immature DC cells; and conducting second induced differentiation culture on the transfected immature DC cells, so as to obtain mature DC cells, wherein the mononuclear cells are isolated from mononuclear cells of peripheral blood of a sample. The method can prepare DC cells safely and efficiently, has a low cost and high efficiency, and can effectively solve the problem of cytotoxicity. The method can be effectively used for immune cell treatment or stimulation of lymphocytes derived from a same patient to produce a targeting cell population containing a large amount of CTL cells, and then the cell population can be used for virus infection immunotherapy to reach better effect.
Owner:SHANGHAI TELEBIO BIOMEDICAL
DC cell based on AFP antigen, targeting immune cell population, preparation method and applications thereof
InactiveCN104830787ASafe and efficient preparationAddress toxicityMammal material medical ingredientsOther foreign material introduction processesAntigenPeripheral blood mononuclear cell
The invention discloses a DC cell based on AFP antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of the DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by AFP antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, the DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.
Owner:SHANGHAI TELEBIO BIOMEDICAL
Method for in-vitro preparation of tumor antigen-specific CD8+ T memory stem cells
ActiveCN105802908AIncrease intakeSpecific Tscm has good anti-tumor effectBlood/immune system cellsAntibody medical ingredientsDendritic cellLymphocytic cell
The invention relates to a method for in-vitro preparation of tumor antigen-specific CD8+ T memory stem cells and application of the tumor antigen-specific CD8+ T memory stem cells in antitumor immune response. The method comprises the following steps: subjecting tumor antigen and immature dendritic cells to co-incubation so as to obtain mature dendritic cells loaded with specific tumor antigen; subjecting the mature dendritic cells and CD8+ initial T cells to co-culture so as to promote generation of tumor antigen-specific CD8+ T memory stem cells; and separating out the CD8+ T memory stem cells capable of specifically recognizing specific tumor cells. The tumor antigen-specific CD8+ T memory stem cells prepared by using the method has good antineoplastic effect, high specificity and few adverse reaction.
Owner:FUDAN UNIV SHANGHAI CANCER CENT
DC cell based on SP17 antigen, targeting immune cell population, preparation method and applications thereof
InactiveCN104830797APowerful killImprove immunityMammal material medical ingredientsOther foreign material introduction processesAntigenPeripheral blood mononuclear cell
The invention discloses a DC cell based on SP17 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by SP17 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.
Owner:SHANGHAI TELEBIO BIOMEDICAL
Method to measure a t cell response and its uses to qualify antigen-presenting cells
A method to characterize a T-cell response of a final population of T-lymphocytes resulting from the co-incubation of an initial population of T lymphocytes with a composition of antigen-presenting cells (APCs), said method comprising the steps of a) simultaneous measuring on a single cell basis at least two parameters: (i) proliferation of T lymphocytes and (ii) presence of a T cell antigen receptor on the surface of T lymphocytes and / or presence of at least one biological molecule produced by T lymphocytes, and the attribution of a positive or a negative value to each of these parameters, and b) classification of the final T-lymphocytes population into 2n different subsets of T lymphocytes, n being the number of parameters, each subset being characterized by a positive or a negative value respectively to each parameter and the determination of the proportion of T lymphocytes present in each subset with respect to the number of T lymphocytes in the final population, with said proportion being characteristic of the T-cell response. Use of the method for batch release assay and potency assay.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE +1
Method of generating multilineage potential cells from lymphocytes
InactiveUS20170145381A1Promote maintenance of viability and growthEasy maintenancePharmaceutical delivery mechanismSkeletal disorderCD20Directed differentiation
Owner:FUWAN
CEA antigen based DC cell and targeting immune cell population, and preparation method and application thereof
InactiveCN104830779ASafe and efficient preparationAddress toxicityMammal material medical ingredientsOther foreign material introduction processesAntigenAbnormal tissue growth
The invention discloses a DC cell and a targeting immune cell population, and a preparation method and application thereof. The preparation method of DC cells includes the steps of: conducting first induced differentiation culture on mononuclear cells in order to obtain immature DC cells; transfecting the immature DC cells by using CEA antigen mRNA, so as to obtain transfected immature DC cells; and conducting second induced differentiation culture on the transfected immature DC cells, so as to obtain mature DC cells, wherein the mononuclear cells are isolated from mononuclear cells of peripheral blood of a sample. The method can prepare DC cells safely and efficiently, has a low cost and high efficiency, and can effectively solve the problem of cytotoxicity. The method can be effectively used for immune cell treatment or stimulation of lymphocytes derived from a same patient to produce a targeting cell population containing a large amount of CTL cells, and then the cell population can be used for tumor immunotherapy to reach better effect.
Owner:SHANGHAI TELEBIO BIOMEDICAL
Method for inducing immunosuppressive b-lymphocytes from human body peripheral blood
The present invention relates to the technical field of biology, specifically to induced culture and purification of human suppressive b-lymphocytes and applications of a potential cell therapy method in autoimmune diseases. According to the method, human peripheral blood is sterilely sampled, LymphoprepTM (Axis-Shield) is adopted to separate human mononuclearcell, the separated cell is placed in a 10% FBS-containing RPMI1640 culture medium to culture, and concurrently 50 ng / ml of human recombinant BAFF cytokine is added at a first day, a third day and a fifth day to induce suppressive b-lymphocyte production. According to the present invention, the BAFF is adopted for differentiation of the human peripheral blood B cells into the suppressive b-lymphocytes through in vitro induction, wherein the suppressive b-lymphocytes express IL-10, and have T lymphocyte proliferation inhibition capability.
Owner:JIANGSU UNIV
Making method of immune complex adsorption cells
InactiveCN104293836ALow costThe detection process is fastGenetic engineeringFermentationImmune complex depositionCell membrane
The invention discloses a making method of immune complex adsorption cells. The method comprises the steps of vector construction, virus packaging production, immortalized B lymphocyte production and gene transfection. A set of immortalized cells respectively carrying specific genes is made, has immortalization (infinite proliferation) ability, can express a certain immune complex receptor on the surfaces on the cells, and an immune complex analysis group is established through amplifying cultured cells, and allows all immune complexes in blood or body tissues to be identified, classified and quantified. The method has the characteristics of low cost, infinite proliferation, fast detection speed, simple operation and the like. The aim of the invention is to obtain the immortalized B lymphocytes, the B lymphocytes can stably express an immune complex receptor gene, the receptor can exist on cell membranes, and can be combined with one corresponding immune complex not limited to immortalized B cells, outside the cells,.
Owner:CHANGSHA YINGRUN BIOTECH
DC cell based on SPANXA1 antigen, targeting immune cell population, preparation method and applications thereof
InactiveCN104830796ASafe and efficient preparationAddress toxicityMammal material medical ingredientsOther foreign material introduction processesAntigenPeripheral blood mononuclear cell
The invention discloses a DC cell based on SPANXA1 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by SPANXA1 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.
Owner:SHANGHAI TELEBIO BIOMEDICAL
DC cell based on BCG1 antigen, targeting immune cell population, preparation method and applications thereof
InactiveCN104830792APowerful killImprove immunityMammal material medical ingredientsOther foreign material introduction processesAntigenPeripheral blood mononuclear cell
The invention discloses a DC cell based on BCG1 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by BCG1 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.
Owner:SHANGHAI TELEBIO BIOMEDICAL
DC cell based on HBV1 antigen, targeting immune cell population, preparation method and applications thereof
InactiveCN104830783ASafe and efficient preparationAddress toxicityMammal material medical ingredientsOther foreign material introduction processesAntigenPeripheral blood mononuclear cell
The invention discloses a DC cell based on HBV1 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of the DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by HBV1 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, the DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.
Owner:SHANGHAI TELEBIO BIOMEDICAL
Biological tissue photoacoustic circulating tumor cell detection and diagnosis device and method
InactiveCN105310657AOvercoming distractionsNormal blood cellsDiagnostic recording/measuringSensorsMedicine.hematologyCytotoxicity
Owner:周辉
DC cell based on PSA antigen, targeting immune cell population, preparation method and applications thereof
InactiveCN104830799ASafe and efficient preparationAddress toxicityMammal material medical ingredientsOther foreign material introduction processesPeripheral blood mononuclear cellPsa antigen
The invention discloses a DC cell based on PSA antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by PSA antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.
Owner:SHANGHAI TELEBIO BIOMEDICAL
DC cell based on P53 antigen, targeting immune cell population, preparation method and applications thereof
InactiveCN104830803APowerful killImprove immunityMammal material medical ingredientsOther foreign material introduction processesAntigenPeripheral blood mononuclear cell
The invention discloses a DC cell based on P53 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by P53 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.
Owner:SHANGHAI TELEBIO BIOMEDICAL
An amphiphilic self-assembled ultrashort peptide nanohemostatic material
ActiveCN105085622BRich varietyLow toxicityPeptidesAbsorbent padsSpecific immunityBiocompatibility Testing
The invention aims to provide amphipathic self-assembly ultra-short peptide. The amino acid sequence general formula of the peptide is I3-X-Q-G-K(1-2). According to the amphipathic self-assembly ultra-short peptide, the content of amino acid is small, synthesis cost is low, and synthesis conditions can be controlled easily; high-strength in-situ hydrogel can be formed at the moment the ultra-short peptide makes contact with blood, so that a fast hemostatic function is achieved; meanwhile, the series short peptide is low in toxicity, good in biocompatibility and capable of not causing a non-specific immunity reaction of lymphocyte, thereby being an ideal nano hemostatic material. By the application of the amphipathic self-assembly ultra-short peptide, the variety of existing nano medicine materials can be enriched, and it is of great significance to the life and health of people.
Owner:CHINA UNIV OF PETROLEUM (EAST CHINA)
DC cell based on SURVIVIN antigen, targeting immune cell population, preparation method and applications thereof
InactiveCN104830801ASafe and efficient preparationAddress toxicityMammal material medical ingredientsOther foreign material introduction processesAbnormal tissue growthPeripheral blood mononuclear cell
The invention discloses a DC cell based on SURVIVIN antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by SURVIVIN antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.
Owner:SHANGHAI TELEBIO BIOMEDICAL
DC cell based on SCC antigen, targeting immune cell population, preparation method and applications thereof
InactiveCN104830798APowerful killImprove immunityMammal material medical ingredientsOther foreign material introduction processesPeripheral blood mononuclear cellMonocyte
The invention discloses a DC cell based on SCC antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by SCC antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.
Owner:SHANGHAI TELEBIO BIOMEDICAL
DC cell based on HPVE6 antigen, targeting immune cell population, preparation method and applications thereof
InactiveCN104830785ASafe and efficient preparationAddress toxicityMammal material medical ingredientsOther foreign material introduction processesAntigenPeripheral blood mononuclear cell
The invention discloses a DC cell based on HPVE6 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by HPVE6 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, the DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.
Owner:SHANGHAI TELEBIO BIOMEDICAL
A method for preparing tumor antigen-specific CD8+ stem cell-like memory T lymphocytes in vitro
ActiveCN105802908BIncrease intakeSpecific Tscm has good anti-tumor effectBlood/immune system cellsAntibody medical ingredientsMemory T-LymphocyteDendritic cell
The invention relates to a method for in-vitro preparation of tumor antigen-specific CD8+ T memory stem cells and application of the tumor antigen-specific CD8+ T memory stem cells in antitumor immune response. The method comprises the following steps: subjecting tumor antigen and immature dendritic cells to co-incubation so as to obtain mature dendritic cells loaded with specific tumor antigen; subjecting the mature dendritic cells and CD8+ initial T cells to co-culture so as to promote generation of tumor antigen-specific CD8+ T memory stem cells; and separating out the CD8+ T memory stem cells capable of specifically recognizing specific tumor cells. The tumor antigen-specific CD8+ T memory stem cells prepared by using the method has good antineoplastic effect, high specificity and few adverse reaction.
Owner:FUDAN UNIV SHANGHAI CANCER CENT
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com